How Novartis AG stacks up

NVS · against 14 other Healthcare companies of similar size

Overall

63/ 100

Above the middle of the pack.

Ranked #3 of 15 · scores higher than 71% of peers

Bars: peers in each 10-point band of the overall score

5 peers with an overall score of 60–69, including NVS · Click a bar to see the companies

The four scores behind it

Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)

Valuation#4 of 15Score 68 / 100 · beats 79%Growth#7 of 15Score 57 / 100 · beats 57%Profitability#3 of 15Score 94 / 100 · beats 79%Risk#6 of 15Higher relative risk · safety 31 · beats 64%

Ranking by overall score

Top 5 and the companies ranked around NVS

Rank	Company	Market cap	Overall	Valuation	Growth	Profitability	Risk
1	Novo Nordisk A/SNVO · US-listed	177.5B USD	71	92	60	99	2 / 2
2	Intuitive Surgical, Inc.ISRG · US-listed	155.7B USD	64	47	73	94	1 / 2
3	AstraZeneca PLCAZN · US-listed	285.2B USD	63	66	64	86	1 / 2
3	GSK plcGSK.BA · Latin America	162.93T ARS (≈$162.9B)	63	82	72	78	2 / 2
3	Novartis AGNVS · US-listed	302.7B USD	63	68	57	94	2 / 2
6	Roche Holding AGRO.SW · Europe	317.9B CHF (≈$365.6B)	60	70	49	97	2 / 2
7	Amgen Inc.AMGN · US-listed	249.4B USD	55	60	63	90	2 / 2
8	AbbVie Inc.ABBV · US-listed	505.4B USD	53	48	66	87	2 / 2
9	Danaher CorporationDHR · US-listed	161.8B USD	50	53	47	68	2 / 2

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score

Bringing the fundamentals into focus…